HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Major depression with psychotic features — Clinical Guidelines

Overview

Major depression with psychotic features is a severe subtype of depression characterized by the presence of psychotic symptoms such as delusions or hallucinations alongside depressive symptoms. 1

Diagnosis

Diagnosis requires a major depressive episode with prominent psychotic symptoms (delusions, hallucinations).

No specific diagnostic tests; clinical assessment is crucial.

Differentiating from bipolar disorder with psychotic features is essential. 1

Management

First-line treatments: Combination therapy of antidepressants (AD) and antipsychotics (AP) is recommended. 1 2

Specific drug classes:

- Antipsychotics: Common choices include atypical antipsychotics like quetiapine or olanzapine. 1 - Antidepressants: Tricyclic antidepressants or selective serotonin reuptake inhibitors (SSRIs) may be used, often in combination. 1

Adjunctive treatments: Carbamazepine has shown efficacy in refractory cases 3.

Maintenance therapy: Combination of AD and AP is associated with lower relapse rates compared to monotherapy. 2

Special Populations

Pregnancy: Specific guidelines for pharmacological management during pregnancy are not detailed in the provided abstracts. 1 2 3

Pediatrics: No specific data provided in the abstracts regarding treatment in pediatric populations. 1 2 3

Elderly: No distinct recommendations for elderly patients are provided; caution with polypharmacy is implied. 1 2 3

Comorbidities: Management should consider comorbid psychiatric conditions, though specific guidance is limited in the abstracts. 1 2 3

Key Recommendations

Use combination therapy of antidepressants and antipsychotics as first-line treatment for psychotic depression. (Evidence: Strong 1 2)

Consider maintenance therapy with AD and AP combination to reduce relapse rates compared to monotherapy. (Evidence: Moderate 2)

Explore carbamazepine as an adjunctive treatment option for patients who do not respond adequately to standard treatments. (Evidence: Weak 3)

References

1 Oliva V, Possidente C, De Prisco M, Fico G, Anmella G, Hidalgo-Mazzei D et al.. Pharmacological treatments for psychotic depression: a systematic review and network meta-analysis. The lancet. Psychiatry 2024. link00006-3) 2 Al-Wandi A, Holmberg C, Landén M, Nordenskjöld A. A systematic review and meta-analysis of maintenance treatment for psychotic depression. Nordic journal of psychiatry 2022. link 3 Schaffer CB, Mungas D, Rockwell E. Successful treatment of psychotic depression with carbamazepine. Journal of clinical psychopharmacology 1985. link

Major depression with psychotic features